The drug that is being followed with a telescope is Merck & Co., Inc (NYSE:MRK)'s BACE inhibitor. This very recently began its Phase-II/III study with patients suffering from mild-to-moderate Alzheimer's disease.

3 Drug Launches You Need to Know in 2013: Pfizer, NPS Pharma, Ariad The Food and Drug Administration (FDA) made a groundbreaking policy change last year that is having a large impact on the biotech industry and creating a big opportunity for investors ...

Merck & Co., Inc. (NYSE:MRK) The best thing about the stock market is that you can make money in either direction.

A classic example is that of the 2011 acquisition of Inspire by Merck & Co., Inc. (NYSE:MRK). $430 million was considered a great offer - at $5 a share, it represented a 26% premium to Inspire's share price at that time.

It started running in 1980, when a series of interest rate increases by the Federal Reserve finally broke the back of inflation, and it galloped onward for more than three decades.

Eli Lilly & Co. (NYSE:LLY) told the Wall Street Journal that it doesn't believe the liver toxicity has to do with the mechanism of inhibiting BACE and is most likely an off-target effect.

Several securities within the pharmaceutical sector have experienced notable spikes in short interest lately, despite their technical prowess.

In what is becoming a trend, options trading on Merck & Co., Inc. (NYSE:MRK) is heavy today, with 60,000 contracts changing hands -- nearly 90% ahead of the norm.

Merck & Co., Inc (NYSE:MRK) is axing jobs and also eliminating an entire peel of senior management from its R&D arm.

Merck & Co. is cutting jobs and stripping a layer of senior management from its research-and-development arm, as its new chief seeks to turnaround a unit he said is marked by "the complexity of our organizational design.